Importer of Controlled Substances Application: Sharp Clinical Services, Inc., 17206-17207 [2021-06687]
Download as PDF
<![CDATA[
17206
Federal Register / Vol. 86, No. 61 / Thursday, April 1, 2021 / Notices
Domestic Like Product that have
occurred in the United States or in the
market for the Subject Merchandise in
the Subject Country after 2014, and
significant changes, if any, that are
likely to occur within a reasonably
foreseeable time. Supply conditions to
consider include technology;
production methods; development
efforts; ability to increase production
(including the shift of production
facilities used for other products and the
use, cost, or availability of major inputs
into production); and factors related to
the ability to shift supply among
different national markets (including
barriers to importation in foreign
markets or changes in market demand
abroad). Demand conditions to consider
include end uses and applications; the
existence and availability of substitute
products; and the level of competition
among the Domestic Like Product
produced in the United States, Subject
Merchandise produced in the Subject
Country, and such merchandise from
other countries.
(13) (OPTIONAL) A statement of
whether you agree with the above
definitions of the Domestic Like Product
and Domestic Industry; if you disagree
with either or both of these definitions,
please explain why and provide
alternative definitions.
Authority: This proceeding is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to § 207.61 of the Commission’s
rules.
By order of the Commission.
Issued: March 23, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–06356 Filed 3–31–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–815]
Bulk Manufacturer of Controlled
Substances Application: Bulk
Manufacturer of Marihuana: ThinkPur,
LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
jbell on DSKJLSW7X2PROD with NOTICES
AGENCY:
The Drug Enforcement
Administration (DEA) is providing
notice of an application it has received
from an entity applying to be registered
to manufacture in bulk basic class(es) of
controlled substances listed in schedule
I. DEA intends to evaluate this and other
SUMMARY:
VerDate Sep<11>2014
19:02 Mar 31, 2021
Jkt 253001
pending applications according to its
regulations governing the program of
growing marihuana for scientific and
medical research under DEA
registration.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefor, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 1, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW 8701
Morrissette Drive, Springfield, Virginia
22152. To ensure proper handling of
comments, please reference Docket
No—DEA–XXX in all correspondence,
including attachments.
SUPPLEMENTARY INFORMATION: The
Controlled Substances Act (CSA)
prohibits the cultivation and
distribution of marihuana except by
persons who are registered under the
CSA to do so for lawful purposes. In
accordance with the purposes specified
in 21 CFR 1301.33(a), DEA is providing
notice that the entity identified below
has applied for registration as a bulk
manufacturer of schedule I controlled
substances. In response, registered bulk
manufacturers of the affected basic
class(es), and applicants therefor, may
file written comments on or objections
of the requested registration, as
provided in this notice. This notice does
not constitute any evaluation or
determination of the merits of the
application submitted.
The applicant plans to manufacture
bulk active pharmaceutical ingredients
(API) for product development and
distribution to DEA registered
researchers. If the application for
registration is granted, the registrant
would not be authorized to conduct
other activity under this registration
aside from those coincident activities
specifically authorized by DEA
regulations. DEA will evaluate the
application for registration as a bulk
manufacturer for compliance with all
applicable laws, treaties, and
regulations and to ensure adequate
safeguards against diversion are in
place.
As this applicant has applied to
become registered as a bulk
manufacturer of marihuana, the
application will be evaluated under the
criteria of 21 U.S.C. 823(a). DEA will
conduct this evaluation in the manner
described in the rule published at 85 FR
82333 on December 18, 2020, and
reflected in DEA regulations at 21 CFR
part 1318.
DATES:
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
In accordance with 21 CFR
1301.33(a), DEA is providing notice that
on January 11, 2020, ThinkPur, LLC, 46
FM 3351 North, Bergheim, Texas 78004
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
Controlled
substance
Drug code
Marihuana Extract
Schedule
7350
I
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–06688 Filed 3–31–21; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–817]
Importer of Controlled Substances
Application: Sharp Clinical Services,
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Sharp Clinical Services, Inc.,
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 3, 2021. Such persons
may also file a written request for a
hearing on the application on or before
May 3, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on February 15, 2021,
Sharp Clinical Services, Inc., 2400
SUMMARY:
E:\FR\FM\01APN1.SGM
01APN1
Federal Register / Vol. 86, No. 61 / Thursday, April 1, 2021 / Notices
week ‘‘off’’ period and making the
application of the TUR trigger
retroactive to March 18, 2020. As such,
the state will trigger back ‘‘on’’ a high
unemployment period with an effective
date of June 7, 2020.
Controlled
• Based on the data submitted by
Drug
code
Schedule
substance
Hawaii for the week ending February
28, 2021, Hawaii’s 13-week insured
Gamma Hydroxybutyric Acid .......
2010
I unemployment rate (IUR) was 4.89
percent, falling below the 5.0 percent
3,4-Methylenedioxy
IUR threshold necessary to remain ‘‘on’’
methamphetamine ................
7405
I EB. Therefore, the EB period for Hawaii
ended on March 6, 2021. The state will
remain in an ‘‘off’’ period for a
The company plans to import the
minimum of 13 weeks.
listed controlled substances for clinical
• Based on the data submitted by
trials. No other activity for this drug
Puerto Rico for the week ending
code is authorized for this registration.
February 27, 2021, Puerto Rico’s 13Approval of permit applications will
week IUR was 4.96 percent, falling
occur only when the registrant’s
business activity is consistent with what below the 5.0 percent IUR threshold
necessary to remain ‘‘on’’ EB. Therefore,
is authorized under 21 U.S.C. 952(a)(2).
the EB period for Puerto Rico ended on
Authorization will not extend to the
March 20, 2021. The state will remain
import of Food and Drug
in an ‘‘off’’ period for a minimum of 13
Administration-approved or nonweeks.
approved finished dosage forms for
• Based on the data submitted by
commercial sale.
Washington for the week ending
William T. McDermott,
February 20, 2021, Washington’s 13Assistant Administrator.
week IUR was 4.95 percent, falling
[FR Doc. 2021–06687 Filed 3–31–21; 8:45 am]
below the 5.0 percent IUR threshold
BILLING CODE P
necessary to remain ‘‘on’’ EB. Therefore,
the EB period for Washington ended on
March 13, 2021. The state will remain
in an ‘‘off’’ period for a minimum of 13
DEPARTMENT OF LABOR
weeks.
Employment and Training
The trigger notice covering state
Administration
eligibility for the EB program can be
found at: https://ows.doleta.gov/
Notice of a Change in Status of the
unemploy/claims_arch.as.
Extended Benefit (EB) Program for
Information for Claimants
California, Colorado, Hawaii, Puerto
Rico, and Washington
The duration of benefits payable in
the EB program, and the terms and
AGENCY: Employment and Training
conditions on which they are payable,
Administration, Labor.
are governed by the Federal-State
ACTION: Notice.
Extended Unemployment Compensation
Act of 1970, as amended, and the
This notice announces a changes in
operating instructions issued to the
benefit period eligibility under the EB
states by the U.S. Department of Labor.
program that have occurred since the
In the case of a state beginning an EB
publication of the last notice regarding
period, the State Workforce Agency will
the States’ EB status:
furnish a written notice of potential
• Colorado’s state law allows for the
temporary adoption of the optional total entitlement to each individual who has
unemployment rate (TUR) trigger during exhausted all rights to regular benefits
and is potentially eligible for EB (20
periods of 100% Federal financing.
Recent TUR data released by the Bureau CFR 615.13(c)(1)).
Persons who believe they may be
of Labor Statistics reflected Colorado’s
entitled
to EB, or who wish to inquire
TUR as meeting the conditions
about their rights under the program,
necessary to be triggered ‘‘on’’ EB,
should contact their State Workforce
however the state was in a mandatory
Agency.
13-week ‘‘off’’ period beginning
November 28, 2020. That mandatory
FOR FURTHER INFORMATION CONTACT: U.S.
‘‘off’’ period was expired February 27,
Department of Labor, Employment and
2021, and as such Colorado is triggered
Training Administration, Office of
‘‘on’’ to EB effective February 28, 2021.
Unemployment Insurance Room
• The State of California enacted
S–4524, Attn: Thomas Stengle, 200
legislation waiving the mandatory 13Constitution Avenue NW, Washington,
jbell on DSKJLSW7X2PROD with NOTICES
Baglyos Circle, Bethlehem,
Pennsylvania 18020–8024, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
VerDate Sep<11>2014
19:02 Mar 31, 2021
Jkt 253001
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
17207
DC 20210, telephone number (202) 693–
2991 (this is not a toll-free number) or
by email: Stengle.Thomas@dol.gov.
Signed in Washington, DC.
Suzan G. LeVine,
Principal Deputy Assistant Secretary for
Employment and Training.
[FR Doc. 2021–06712 Filed 3–31–21; 8:45 am]
BILLING CODE 4510–FW–P
NATIONAL SCIENCE FOUNDATION
Notice of Intent To Seek Approval To
Renew With Changes an Information
Collection
National Science Foundation.
Notice and request for
comments.
AGENCY:
ACTION:
The National Science
Foundation (NSF) is announcing plans
to request establishment and clearance
of this collection. In accordance with
the requirements of the Paperwork
Reduction Act of 1995, we are providing
opportunity for public comment on this
action. After obtaining and considering
public comment, NSF will prepare the
submission requesting that OMB
approve clearance of this collection for
no longer than three years.
DATES: Written comments on this notice
must be received by June 1, 2021 to be
assured of consideration. Comments
received after that date will be
considered to the extent practicable.
FOR FURTHER INFORMATION CONTACT:
Suzanne H. Plimpton, Reports Clearance
Officer, National Science Foundation,
2415 Eisenhower Avenue, Room W
18000, Alexandria, Virginia 22314; or
send email to splimpto@nsf.gov.
Individuals who use a
telecommunications device for the deaf
(TDD) may call the Federal Information
Relay Service (FIRS) at 1–800–877–
8339, which is accessible 24 hours a
day, 7 days a week, 365 days a year
(including federal holidays).
Instructions: Please submit one copy
of your comments by only one method.
All submissions received must include
the agency name and collection name
identified above for this information
collection. Commenters are strongly
encouraged to transmit their comments
electronically via email. Comments,
including any personal information
provided become a matter of public
record. They will be summarized and/
or included in the request for Office of
Management and Budget approval of the
information collection request.
SUPPLEMENTARY INFORMATION:
Comments: Comments are invited on
(a) whether the proposed collection of
SUMMARY:
E:\FR\FM\01APN1.SGM
01APN1
]]>Agencies
[Federal Register Volume 86, Number 61 (Thursday, April 1, 2021)]
[Notices]
[Pages 17206-17207]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06687]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-817]
Importer of Controlled Substances Application: Sharp Clinical
Services, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Sharp Clinical Services, Inc., has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before May 3, 2021.
Such persons may also file a written request for a hearing on the
application on or before May 3, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on February 15, 2021, Sharp Clinical Services, Inc.,
2400
[[Page 17207]]
Baglyos Circle, Bethlehem, Pennsylvania 18020-8024, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid....................... 2010 I
3,4-Methylenedioxymethamphetamine............... 7405 I
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
clinical trials. No other activity for this drug code is authorized for
this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-06687 Filed 3-31-21; 8:45 am]
BILLING CODE P
